Accuracy of fecal calprotectin and endoscopic narrow band imaging in the prediction of severity of inflammatory bowel diseases
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231614Keywords:
Faecal calprotectin, Colonoscopy, Narrow band imaging, Inflammatory bowel disease, ColitisAbstract
Background: Fecal calprotectin is a noninvasive and accurate marker of inflammatory bowel disease. In addition to aiding in diagnosis, it also predicts inflammatory bowel disease (IBD) relapses and the severity of the disease. Objectives of current study were evaluate the accuracy of Fecal calprotectin and Narrow band imaging for prediction severity in inflammatory bowel disease.
Methods: After informed written consent and ethical clearance, the study prospectively included 50 patients of IBD. Quantitative measurement of Calprotectin was done by ELISA kit (Eagle Biosciences, Nashua). Endoscopy activity was calculated using Narrow band imaging.
Results: Out of 50 patients, Males outnumbered the females with a ratio of 2.1. Increased frequency of stools was the most common symptom (94%). 39 (78%) patients had features ulcerative colitis while as 9 (18%) patients had features of Crohn’s disease. Total of 42 (84%) patients had elevated levels of Fecal Calprotectin. The severity of IBDs increased significantly when the Fecal Calprotectin level rises (p value >0.05). The relationship between endoscopic and histological scores to detect disease severity in IBD was statistically insignificant (p value=0.85). The accuracy of the fecal calprotectin levels was found to be 84%, sensitivity 87.5%, and specificity was 50%. The positive and negative predictive values were 97.6% and 12.55% respectively. 47 (94%) patients received medical treatment. 3 (7.7%) patients of UC were subjected to surgical intervention.
Conclusions: Fecal calprotectin is a valuable and non-invasive marker with good sensitivity and specificity for the diagnosis, evaluation of the severity, and monitoring of IBD activity.
References
Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002; 16(1):51-60.
Williams N, Ronan O’Connell P, McCaskie A. The pancreas. In: Bailey & Love’s Short Practice of Surgery. 28th ed. Boca Raton, FL: CRC Press; 2023: 1318-34.
Prantera C, Cottone M, Pallone F. Mesalamine in the treatment of mild to moderate active Crohn‘s ileitis, results of a randomised multicenter trial. Gastroenterology. 1999;116:521-6.
Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63(3):629-42.
Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163-74.
Present DH, Rutgeerts P, Targan S, Hanauer S, Mayer L, Hogezand R, et al. Infliximab for the treatment of fistulas in patients with Crohn‘s disease. New Eng J Med. 1999;340:1398-405.
Kühn F, Klar E. Surgical principles in the treatment of ulcerative colitis. Viszeralmedizin. 2015;31(4):246-50.
Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn‘s disease. Dis Mon. 2018;64:20-57.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369(9573):1627-40.
Zhang YZ, Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26-42.
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-57.
Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15(1):79-94.
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-22.
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol. 2005;20: 1691-5.
Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointest Endosc. 1977;23:150-4.
Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42:232-7
Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92:181-5.
Haskell H, Andrews CW, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, et al. Pathologic features and clinical significance of backwash‖ ileitis in ulcerative colitis. Am J Surg Pathol. 2005;29:1472-81.
Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42:232-7.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-45.
Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639-51.
Vaos G, Kostakis ID, Zavras N, Chatzemichael A. The role of calprotectin in pediatric disease. Biomed Res Int. 2013;2013:542.
Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014;20:363-75.
Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med. 2021;8: 765.
